

28TH UNIVERSITY OF CHICAGO COMPREHENSIVE CANCER CENTER

# DEVELOPMENTAL THERAPEUTICS SYMPOSIUM

Participants at this unique forum will critically analyze data from important clinical studies, engage in thought-provoking discussions on cutting-edge investigational agents in active trials, and delve into the scientific rationale and results of studies featuring novel cancer treatments. Gain actionable insights to seamlessly integrate these innovative therapies into your clinical practice, contribute to the development and success of impactful trials, and strengthen your role as a leader in the oncology community. This activity will empower you with the latest knowledge and tools to effectively implement precision medicine in cancer care, driving improved outcomes for your patients.



AT THE FOREFRONT

**UChicago Medicine**

Comprehensive Cancer Center



AT THE FOREFRONT



**UChicago Medicine**

Comprehensive Cancer Center

The University of Chicago  
Comprehensive Cancer Center  
5841 S. Maryland Avenue  
Chicago, IL 60637

Follow us on Twitter: @UChicagoCME

**SCAN OR VISIT TO REGISTER TODAY!**

[www.UofCDevelopmentalTherapeuticsSymposium.org](http://www.UofCDevelopmentalTherapeuticsSymposium.org)

**QUESTIONS?** Contact Meeting Achievements at  
[kristen@meetingachievements.com](mailto:kristen@meetingachievements.com) Or 219.465.1115

ACCREDITED BY UNIVERSITY OF CHICAGO



AT THE FOREFRONT

**UChicago Medicine**

Comprehensive Cancer Center

28TH UNIVERSITY OF CHICAGO COMPREHENSIVE CANCER CENTER

# DEVELOPMENTAL THERAPEUTICS SYMPOSIUM

**MAY 2, 2025**

**DAVID RUBENSTEIN FORUM  
CHICAGO, ILLINOIS**

## PROGRAM INFORMATION

### TARGET AUDIENCE

This activity is designed for physicians and other healthcare professionals who diagnose, screen, and treat patients with cancer.

### LEARNING OBJECTIVES

After this activity, participants will be able to:

- Recall new approaches to pre- and post-FDA approval for dosing and scheduling of anti-cancer agents;
- Recognize the therapeutic ratio of novel agents and approaches to define dose reductions that maintain efficacy;
- State the clinical effects of novel immunotherapeutic agents, including novel checkpoint inhibitors, bispecific antibodies, and novel cellular therapies;
- Identify how to assess patient suitability for participation in ongoing and upcoming cancer clinical trials and projects;
- Cite the relevant pharmacologic and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches, including novel PET tracer imaging and circulating tumor DNA assays;
- Describe advances in the use of systemic therapies for cancer, including those targeting specific molecular alterations such as DNA repair mutations, specific chromosomal translocations, and tyrosine kinase mutations;
- Assess the status of and developmental pathway for antibody-drug conjugates in solid and hematologic tumors.

### ACCREDITATION AND CREDIT DESIGNATION STATEMENT

**PHYSICIAN CREDIT:** The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of **5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**NURSING CREDIT:** University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Participants who successfully complete the entire activity and complete an evaluation form will earn **5** contact hours.

**AMERICAN BOARD OF INTERNAL MEDICINE MOC PART II CREDIT:** Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **5** MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**OTHER PARTICIPANT CREDIT:** Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by the ACCME, please consult your professional licensing board.

# DEVELOPMENTAL THERAPEUTICS SYMPOSIUM

## AGENDA: MAY 2, 2025

8:15am	<b>CONFERENCE REGISTRATION</b>	12:00pm	<b>LUNCH</b>
8:40am	<b>WELCOME ADDRESS</b> Dr. Toyosi Odenike	12:20pm	<b>CONCURRENT LUNCH BREAKOUTS</b>
8:45am	<b>The Current Landscape of Novel Therapeutics in Breast Cancer</b> Dr. Nan Chen	—	<b>Pursuing Organ Preservation for Patients with Locoregionally Advanced Head and Neck Cancer at The University of Chicago</b> Dr. Everett Vokes
9:10am	<b>New Frontiers: Personalized Treatment Approaches in Head and Neck Cancer</b> Dr. Ari Rosenberg	—	<b>Nursing Session Breakout</b> Livia Szeto, RN Sara Moellering, RN Lauren Wall, RN
9:35am	<b>Novel and Emerging Therapies for Small Cell Lung Cancer</b> Dr. Noura Choudhury	1:05pm	<b>BREAK</b>
10:00am	<b>BREAK</b>	1:30pm	<b>BCMA and Beyond: The Next Generation of Immunotherapies in Multiple Myeloma</b> Dr. Jennifer Cooperrider
10:20am	<b>TILs in the Real World: the UChicago experience with the first FDA approved cell therapy for a solid tumor</b> Dr. Dan Olson	1:55pm	<b>Updates in Novel Therapies for Gynecologic Malignancies</b> Dr. Katherine Kurnit
10:45am	<b>Prostate Cancer: New Targets Beyond the Androgen Receptor</b> Dr. Mohammad Atiq	2:20pm	<b>Novel Radiotherapy Approaches to Locally Advanced and Metastatic Malignancies</b> Dr. Aditya Juloori
11:10am	<b>Therapeutic Advances in Hodgkin Lymphoma and Their Impact on Quality of Life</b> Dr. Adam Duvall	2:45pm	<b>CLOSING REMARKS</b>
11:35am	<b>Targeted Therapeutics in Acute Leukemia and Myeloid Malignancies</b> Dr. Anand Patel		

### COURSE DIRECTOR



**Toyosi Odenike, MD**  
Professor of Medicine  
Director, Leukemia Program  
University of Chicago

**REGISTER TODAY!**  
SCAN or VISIT:

